Merck KGaA: ovarian cancer drug fails to meet trial goal

(CercleFinance.com) - Merck KGaA and its US partner Pfizer said on Monday that their treatment for ovarian cancer has failed to reach a primary endpoint in a late-stage trial.


A Phase III trial evaluating avelumab alone or in combination with chemotherapy did not meet the primary endpoints of overall survival or progression-free survival, the drugmakers said.

The multi-center, randomized study included 566 women with ovarian cancer that is resistant or refractory to platinum chemotherapy.

Copyright (c) 2018 CercleFinance.com. All rights reserved.